Widely used:Recently Viewed
Clear All
$279 Mln
--
1.2
--
0
-66.58 %
--
--
--
-2359781
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Editas Medicine (EDIT)
| -68.31 | -10.58 | -30.07 | -55.10 | -55.94 | -31.81 | -- |
|
BSE Sensex
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Editas Medicine (EDIT)
| 14.21 | -66.59 | -62.13 | 136.78 | 30.15 | -25.85 | 89.34 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$278.77 Mln
$67.03 Mln
$-45.02 Mln
$279.11 Mln
$38.70 Mln
High
$3.15 - 11.69
82,476,400
NASDAQ: EDIT
Cambridge, MA
https://www.editasmedicine.com
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company... develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Read more
The total asset value of Editas Medicine Inc (EDIT) stood at $ 459 Mln as on 30-Jun-24
The share price of Editas Medicine Inc (EDIT) is $3.21 (NASDAQ) as of 07-Oct-2024 16:08 EDT. Editas Medicine Inc (EDIT) has given a return of -55.94% in the last 3 years.
Editas Medicine Inc (EDIT) has a market capitalisation of $ 279 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Editas Medicine Inc (EDIT) is 1.20 times as on 04-Oct-2024, a 62% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Editas Medicine Inc (EDIT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Editas Medicine Inc (EDIT) and enter the required number of quantities and click on buy to purchase the shares of Editas Medicine Inc (EDIT).
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
The CEO & director of Dr. Gilmore O'Neill M.D.. is Editas Medicine Inc (EDIT), and CFO & Sr. VP is Dr. Gilmore O'Neill M.D..
There is no promoter pledging in Editas Medicine Inc (EDIT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Editas Medicine Inc. (EDIT) | Ratios |
|---|---|
|
Return on equity(%)
|
-66.58
|
|
Operating margin(%)
|
-312.37
|
|
Net Margin(%)
|
-288.59
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Editas Medicine Inc (EDIT) was $-45 Mln.
$-0.17
